Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus oxaliplatin versus gemcitabine plus vinorelbine for salvage treatment of metastatic triple-negative breast cancer
ChiCTR-IPR-14005682Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital Breast Disease Center
- Start
- Jan 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur and oxaliplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Chongqing University Cancer Hospital Breast Disease Center. Primary endpoint: Diameter of measurable lesions. Started Jan 2015; status: recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005682.